View in EDS

EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective.

Saved in:
Bibliographic Details
Title: EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective.
Authors: Liu, T1 (AUTHOR), Purser, M1 (AUTHOR), Gong, C2 (AUTHOR), Elsea, D2 (AUTHOR), Niehoff, N1 (AUTHOR), Dlotko, E3 (AUTHOR), Migliaccio-Walle, K.2 (AUTHOR), Samyshkin, Y4 (AUTHOR)
Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS112-S112. 1p.
Database: Academic Search Ultimate
Be the first to leave a comment!
You must be logged in first